The University of Liverpool (UoL) has led studies of rotavirus diarrhoea in Malawi since 1997. These studies were designed to facilitate and accelerate the introduction of rotavirus vaccines into childhood Expanded Programme on Immunisation (EPI) programmes in Malawi and other low-income African countries. Vaccines developed by GSK (RotarixÒ) and Merck (RotaTeqÒ) were known to work well in high-income countries but their impact on protecting children in poorer countries was unknown.
A pivotal, Phase III clinical trial of the RotarixÒ rotavirus vaccine was undertaken in Malawi. This first trial of a modern rotavirus vaccine in Africa showed that severe rotavirus diarrhoea episodes were reduced by half, leading to a WHO recommendation in 2009 that all the world's children should receive rotavirus vaccine, with a particularly strong recommendation for those countries with a high burden of diarrhoea deaths.
Case control studies in 2012 - 2014 demonstrated that national vaccination was more than 60% effective in preventing severe rotavirus diarrhoea episodes among infants in urban Malawi, with rotavirus hospitalisations reduced by over 40%. A large, prospectively conducted cohort study of 48,672 live births, then demonstrated that rotavirus vaccination reduced infant diarrhoea deaths by a third in rural Malawi, the first empirical evidence from a low-income country that rotavirus vaccination saves lives. The UoL-led study also demonstrated that rotavirus vaccination provides cost-effective health protection in Malawi.
Working in partnership
The RotarixÒ vaccine was added into Malawi’s infant immunisation schedule in October 2012. In partnership with the Malawi Ministry of Health, the UoL undertook prospectively conducted studies to demonstrate the impact and cost-effectiveness of rotavirus-vaccination across the country.
Through its work in Malawi, UoL contributed to a multi-country African study led by the Centers for Disease Control and Prevention, USA which demonstrated that rotavirus vaccination did not result in the development of intussusception (blockage of the small bowel) in African infants.
Impact of Research
Rotavirus vaccination first introduced in 2012 resulted in immunisation coverage of 81% among one-year-olds by 2013, subsequently increasing to 90%.
Since August 2013 the program in Malawi (Under 5 population of 2,600,000) is estimated to have averted 359,100 cases of rotavirus gastroenteritis, 27,300 inpatient admissions, 1,505 deaths, and 47,600 disability-adjusted-life-years (DALYs).
National rotavirus vaccination programs have been introduced in 38 of the 54 African countries, preventing an estimated 24,200 deaths among children younger than 5 years in sub-Saharan Africa in 2016 alone.
Based on immunisation coverage between 2013 and 2020, the 2016 data allow estimation of the impact of these programs; since August 2013, 169,400 lives were saved across Africa, and approximately 40,400,000 cases of rotavirus gastroenteritis, 3,070,000 inpatient admissions and 5,360,000 DALYs were averted.
Since 2015, most African countries that have introduced rotavirus vaccine have observed an increase in vaccine coverage, with average uptake increasing from 77% to 84% by 2018.
Reader in Paediatric Diseases
Dr. Khuzwayo Jere
Tenure Track Fellow and Virology Research Group Leader at the Malawi-Liverpool Wellcome Trust Clinical Research Programme
Back to: Faculty of Health and Life Sciences